|
N
|
5-Year DFS (%) (95 % CI)
|
HR (95 % CI)
|
p-valuea
|
---|
Age
|
< 35
|
30
|
82.6 [68.2–100]
|
1
| |
≥ 35
|
726
|
90.9 [88.5–93.4]
|
0.5 [0.2–1.3]
|
0.136
|
SBR Grade
|
1–2
|
462
|
93.2 [90.5–95.9]
|
1
| |
3
|
285
|
86 [81.4–91]
|
1.8 [1.1–2.9]
|
0.0138
|
Pathological tumor size
|
pT1
|
391
|
91.2 [87.9–94.5]
|
1
| |
pT2
|
320
|
90 [86.2–94]
|
1.1 [0.7–1.8]
| |
pT3-T4
|
36
|
88.2 [78–99.8]
|
1.1 [0.4–3]
|
0.9514
|
PVI
|
No
|
558
|
92.3 [89.7–95]
|
1
| |
Yes
|
178
|
85 [79–91.4]
|
2.3 [1.4–3.7]
|
0.0007
|
Hormone receptors
|
Negative
|
208
|
86.8 [81.6–92.4]
|
1
| |
Positive
|
526
|
92.5 [89.9–95.2]
|
0.7 [0.4–1.1]
|
0.1059
|
HER2
|
Negative
|
507
|
91 [88–94.1]
|
1
| |
Positive
|
96
|
95.7 [91–100]
|
0.6 [0.2–1.6]
|
0.376
|
IHC subtypes
|
Luminal A
|
289
|
95.1 [92.1–98.2]
|
1
| |
Luminal B/HER2-negative
|
82
|
80.1 [69.8–92]
|
4.3 [2–9.1]
| |
Luminal B/HER2-positive
|
58
|
100 [100–100]
|
0.7 [0.2–3.3]
| |
HER2
|
37
|
89 [77.6–100]
|
1.8 [0.5–6.2]
| |
Triple-negative
|
127
|
87.6 [80.7–95]
|
2.6 [1.2–5.5]
|
0.0006
|
- HR hazard ratio, PVI peritumor vascular invasion
- aunadjusted log-rank test